Clinical trial
PaTHway TRIAL: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Trial, With an Open-Label Extension, Investigating the Safety, Tolerability and Efficacy of TransCon PTH Administered Subcutaneously Daily in Adults With Hypoparathyroidism
NCT04701203 is registered in ClinicalTrials.gov with Ascendis Pharma Bone Diseases A/S as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- PaTHway TRIAL: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Trial, With an Open-Label Extension, Investigating the Safety, Tolerability and Efficacy of TransCon PTH Administered Subcutaneously Daily in Adults With Hypoparathyroidism
- Lead sponsor
- Ascendis Pharma Bone Diseases A/S
- Phase
- Phase 3
- Overall status
- Completed
- Start date
- February 16, 2021
- Completion date
- January 21, 2025
- Enrollment
- 84 (actual)
- Sites
- 21
Conditions
As the registry lists them; a condition with its own page is linked.